<DOC>
	<DOCNO>NCT00530192</DOCNO>
	<brief_summary>This open-label , multicenter pilot study patient advance solid tumor . The primary objective study compare progression-free survival use treatment regimen select molecular profile progression-free survival recent regimen patient progress . To eligible , patient must receive least two line prior chemotherapeutic , hormonal biological regimen advance disease , measurable evaluable , refractory disease clear documentation time treatment start document progression last treatment prior study entry . Eligible patient must undergo available tumor biopsy molecular profiling within 2 month IHC/FISH and/or DNA microarray analysis .</brief_summary>
	<brief_title>Molecular Profiling Protocol ( SCRI-CA-001 )</brief_title>
	<detailed_description />
	<criteria>Metastatic cancer progress 2 prior chemotherapeutic , hormonal biological regimen advance disease . Be define refractory last line therapy Have documentation best clinical response treatment regimen immediately prior enter study Patients symptomatic CNS metastasis Any previous history another malignancy within 5 year study entry Uncontrolled intercurrent illness Known HIV , HBV , HCV infection Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Refractory Cancer</keyword>
	<keyword>Molecular Profile</keyword>
</DOC>